NEW YORK, August 3, 2016 /PRNewswire/ --
The Medical Appliances and Equipment space remains a strong industry which is expected to continue growing given the high need and demand for health care and related instruments. Stock-Callers.com turns investors' attention to the following stocks in review: Neovasc Inc. (NASDAQ: NVCN), MiMedx Group Inc. (NASDAQ: MDXG), InspireMD Inc. (NYSEMKT: NSPR), and Amedica Corp. (NASDAQ: AMDA). Register now and get full and free access to our downloadable research reports on these stocks at: http://stock-callers.com/registration
On Tuesday, Richmond, Canada headquartered Neovasc Inc.'s stock recorded a trading volume of 1.18 million shares, and ended the session down 5.25% at $0.55. The Company's shares have gained 6.27% in the last one month. The stock is trading 10.61% above its 50-day moving average. Moreover, shares of Neovasc, which develops, manufactures, and markets cardiovascular products worldwide, have a Relative Strength Index (RSI) of 54.48.
On August 2nd, 2016, Neovasc announced that it will release its financial results for Q2 2016 on August 9th, 2016, after markets close. The Company will subsequently hold a conference call on that same day, at 4:30 pm Eastern Time hosted by Mr. Alexei Marko, Chief Executive Officer, and Mr. Chris Clark, Chief Financial Officer. Access our complete research report on NVCN for free at: http://stock-callers.com/registration/?symbol=NVCN
Marietta, Georgia headquartered MiMedx Group Inc.'s stock closed the day 2.27% lower at $7.53 and with a total volume of 546,343 shares traded. The Company's shares have advanced 5.24% in the previous three months. The stock is trading 3.42% below its 50-day moving average. Additionally, shares of MiMedx Group, which develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues, and human skin and bone, have an RSI of 41.92.
On July 26th, 2016, MiMedx Group reported record revenue of $57.3 million for Q2 2016, an $11.6 million or 26% increase, over 2015 second quarter revenue of $45.7 million. The Company's Adjusted Gross Margin for Q2 2016 was 88.1% compared to 88.9% in Q2 2015. The company noted that Adjusted Net Income for Q2 2016 was $5.1 million, or $0.05 per diluted common share, a $749,000 decrease as compared to Adjusted Net Income of $5.9 million, or $0.05 per diluted common share, in Q2 2015. The complimentary research report on MDXG can be downloaded at: http://stock-callers.com/registration/?symbol=MDXG
Shares in Boston, Massachusetts headquartered InspireMD Inc. recorded a trading volume of 1.81 million shares, which was higher than their three months average volume of 908,620 shares. The stock ended yesterday's trading session 2.31% lower at $0.18. The Company's shares are trading below their 50-day moving average by 42.02%. Furthermore, shares of InspireMD, which focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex coronary and vascular diseases, have an RSI of 33.76.
On August 1st, 2016, InspireMD announced the listing of the Company's 44,242,424 previously issued warrants on the NYSE MKT. The warrants will commence trading under the ticker symbol "NSPR.WS", after the market opens on August 1st, 2016. On July 7th, 2016, InspireMD announced the closing of a public offering of approximately $14.6 million, which included the issuance of these 44,242,424 warrants. Register for free on Stock-Callers.com and get access to the latest PDF format report on NSPR at: http://stock-callers.com/registration/?symbol=NSPR
Salt Lake City, Utah headquartered Amedica Corp.'s stock finished Tuesday's session 6.55% lower at $0.79. A total volume of 795,556 shares was traded, which was above their three months average volume of 636,130 shares. The Company's shares are trading below their 50-day moving average by 32.00%. Additionally, shares of Amedica, which develops, manufactures, and sells a range of medical devices based on its silicon nitride ceramic technology platform in the United States, Europe, and South America, have an RSI of 33.54.
On August 1st, 2016, Amedica announced that it will release its financial results for Q2 2016 on August 11th, 2016, after the market closes. Following the release, that same day the Company will host a conference call to review its reported quarter's results. Download your free research report on AMDA at: http://stock-callers.com/registration/?symbol=AMDA
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA